相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma
Boris Boell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Lymphoma stem cells: enough evidence to support their existence?
Jose A. Martinez-Climent et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
Donatella Aldinucci et al.
JOURNAL OF PATHOLOGY (2010)
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species
A. M. Vahdat et al.
LEUKEMIA (2010)
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Christian Steidl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Current Approaches to the Management of Pediatric Hodgkin Lymphoma
Jennifer Freed et al.
PEDIATRIC DRUGS (2010)
Circulating clonotypic B cells in classic Hodgkin lymphoma
Richard J. Jones et al.
BLOOD (2009)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Late Effects of Hodgkin's Disease and Its Treatment
Andrea K. Ng et al.
CANCER JOURNAL (2009)
Histone deacetylase inhibitors as anti-neoplastic agents
Nicolas Batty et al.
CANCER LETTERS (2009)
In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma
Pina M. Cardarelli et al.
CLINICAL CANCER RESEARCH (2009)
Heat Shock Protein 90 Inhibitor BIIB021 (CNF2024) Depletes NF-kB and Sensitizes Hodgkin's Lymphoma Cells for Natural Killer Cell-Mediated Cytotoxicity
Boris Boell et al.
CLINICAL CANCER RESEARCH (2009)
Hodgkin lymphoma in the elderly: A clinical review of treatment and outcome, past, present and future
S. J. Proctor et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo
B. Hirsch et al.
CURRENT DRUG TARGETS (2009)
Potent antibody drug conjugates for cancer therapy
Peter D. Senter
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Hodgkin's Lymphoma in Adolescents Treated With Adult Protocols: A Report From the German Hodgkin Study Group
Dennis A. Eichenauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of the Anti-VEGF Monoclonal Antibody Bevacizumab in a Preclinical Model and in Patients With Refractory and Multiple Relapsed Hodgkin Lymphoma
Katrin S. Reiners et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation
Andrea Gallamini et al.
LEUKEMIA & LYMPHOMA (2009)
Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines
Ingo Hartlapp et al.
LEUKEMIA RESEARCH (2009)
New treatment strategies for Hodgkin's lymphoma
Martin Sebastian Staege et al.
LEUKEMIA RESEARCH (2009)
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
A. Younes
Hematology-American Society of Hematology Education Program (2009)
The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
E. S. Jaffe
Hematology-American Society of Hematology Education Program (2009)
Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells
Karl R. N. Baumforth et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
Daniela Buglio et al.
BLOOD (2008)
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe et al.
BLOOD (2008)
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
Yasuhiro Oki et al.
CANCER (2008)
The pathogenesis of classical Hodgkin's lymphoma: what can we learn from analyses of genomic alterations in Hodgkin and Reed-Sternberg cells?
Martin Janz et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Lenalidomide for the treatment of B-cell malignancies
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma
Roger Rautert et al.
LEUKEMIA & LYMPHOMA (2008)
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
Holger Schulz et al.
BLOOD (2008)
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
Catherine M. Bollard et al.
BLOOD (2007)
The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma
Gunila Enblad et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment?
Berthe M. P. Aleman et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study
Andrea Gallamini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma:: A study from the Groupe d'Etude des Lymphomes de l'Adulte
Rene-Olivier Casasnovas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Histone deacetylase inhibitors: gathering pace
Nessa Carey et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death
GV Georgakis et al.
CLINICAL CANCER RESEARCH (2006)
Advances in biology, diagnostics, and treatment of Hodgkin's disease
R Kuppers et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
M Hutchings et al.
BLOOD (2006)
Current strategies and new approaches in the treatment of Hodgkin's lymphoma
Michael Fuchs et al.
PATHOBIOLOGY (2006)
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-Cell malignancies
RJ Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Molecular pathogenesis of Hodgkin's lymphoma
D Re et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas
F Jundt et al.
BLOOD (2005)
The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis
B Böll et al.
BLOOD (2005)
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody
R Schnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunotherapy of Hodgkin's lymphoma
P Borchmann et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Phase I/II study of galiximab, an Anti-CD80 antibody, for relapsed or refractory follicular lymphoma
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
D Re et al.
BLOOD (2005)
Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR
A Dutton et al.
JOURNAL OF PATHOLOGY (2005)
Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
CM Bollard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation
M Broemer et al.
ONCOGENE (2004)
Part I: Hodgkin's lymphoma - molecular biology of Hodgkin and Reed-Sternberg cells
RK Thomas et al.
LANCET ONCOLOGY (2004)
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
P Borchmann et al.
BLOOD (2003)
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
A Kamal et al.
NATURE (2003)
Epstein-Barr virus and oncogenesis: from latent genes to tumours
LS Young et al.
ONCOGENE (2003)
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
BC Ekstrand et al.
BLOOD (2003)
Hodgkin's lymphoma and CD30 signal transduction
R Horie et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma
P Borchmann et al.
BLOOD (2002)
Hodgkin's disease in the elderly: a population-based study
GL Stark et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease
IA Doussis-Anagnostopoulou et al.
JOURNAL OF PATHOLOGY (2002)
Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells
R Horie et al.
ONCOGENE (2002)
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
MR Weihrauch et al.
BLOOD (2001)
分享论文
